Fusion glycoprotein F0 · SINGLE PROTEIN · Human respiratory syncytial virus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Fusion glycoprotein F0 shows approved-linked disease relevance led by Respiratory Syncytial Virus Infection. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q89535. Start with Respiratory Syncytial Virus Infection, then reuse UniProt Q89535 as the stable protein anchor across project notes and exports.
Start with Respiratory Syncytial Virus Infection, then reuse UniProt Q89535 as the stable protein anchor across project notes and exports.
Fusion glycoprotein F0 shows approved-linked disease relevance led by Respiratory Syncytial Virus Infection. 5 more disease programs remain visible in the same review block. 11 linked drugs remain visible in the same block.
Start review with Respiratory Syncytial Virus Infection because it currently carries approved-linked support. Linked drugs include ALX-0171, CLESROVIMAB, MEDI-557, MOTAVIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyFusion glycoprotein F0
Review this target as Fusion glycoprotein F0, mapped to UniProt Q89535. Sequence length is 574 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Fusion glycoprotein F0 as ChEMBL target CHEMBL2364165, mapped to UniProt Q89535. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Fusion glycoprotein F0 is the right protein anchor across sources, using UniProt Q89535 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Respiratory Syncytial Virus Infection is currently framed as approved-linked support. It currently carries 11 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Fusion glycoprotein F0 |
| Target Type | SINGLE PROTEIN |
| Organism | Human respiratory syncytial virus |
| UniProt | Q89535 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Fusion glycoprotein F0 |
| UniProt Accession | Q89535 |
| Component Type | Protein |
| Sequence Length | 574 aa |
Fusion glycoprotein F0
Review this target as Fusion glycoprotein F0, mapped to UniProt Q89535. Sequence length is 574 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Fusion glycoprotein F0 shows approved-linked disease relevance led by Respiratory Syncytial Virus Infection. 5 more disease programs remain visible in the same review block.
Start review with Respiratory Syncytial Virus Infection because it currently carries approved-linked support. Linked drugs include ALX-0171, CLESROVIMAB, MEDI-557, MOTAVIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3410450 | 10.0 | EC50 | 0.1 | Clinical |
| CHEMBL4645289 | 10.0 | EC50 | 0.1 | Preclinical |
| CHEMBL242456 | 9.8 | EC50 | 0.16 | Preclinical |
| CHEMBL4633144 | 9.7 | EC50 | 0.1995 | Preclinical |
| CHEMBL4639647 | 9.7 | EC50 | 0.1995 | Preclinical |
| CHEMBL4647497 | 9.7 | EC50 | 0.1995 | Preclinical |
| CHEMBL4635306 | 9.6 | EC50 | 0.2512 | Preclinical |
| CHEMBL4642009 | 9.6 | EC50 | 0.2512 | Preclinical |
| CHEMBL4644121 | 9.6 | EC50 | 0.2512 | Preclinical |
| CHEMBL4644338 | 9.6 | EC50 | 0.2512 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 10 | 195 | 7.7 |
| assay format | 1 | 1 | 9.8 |
| single protein format | 1 | 0 | — |